Follow-up evaluation of cognitive function in the randomized Alzheimer's disease anti-inflammatory prevention trial and its follow-up study

John Breitner, Laura Baker, Lea Drye, Denis Evans, Constantine G. Lyketsos, Laurie Ryan, Peter Zandi, Hector Hernandez Saucedo, Jane Anau, Brenna Cholerton

Research output: Contribution to journalArticle


Objective: The Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) and Follow-up Study (ADAPT-FS) examined effects of naproxen and celecoxib on cognition in the elderly. We report here results describing trajectories of cognitive evaluation test scores. Methods: A total of 2356 participants completed baseline and at least one follow-up cognitive evaluation between 2001 and 2004. Study treatments were discontinued in 2004, but participants were followed until 2007. A total of 1537 participants were reevaluated in 2010 to 2011. Outcomes include seven cognitive evaluations administered yearly in person in ADAPT and three of these evaluations that were administered by telephone near the end of ADAPT and again in ADAPT-FS. Results: There were no important differences over time by treatment group on anyADAPT cognitive measure, a global composite, or the three cognitive measures reassessed in ADAPT-FS by telephone. Conclusions: Treatment for 1 to 3 years with naproxen or celecoxib did not protect against cognitive decline in older adults with a family history of AD.

Original languageEnglish (US)
Pages (from-to)216-225.e1
JournalAlzheimer's and Dementia
Issue number2
StatePublished - Jan 1 2015



  • Alzheimer's disease
  • Celecoxib
  • Clinical trial
  • Cognitive function
  • Naproxen
  • Nonsteroidal anti-inflammatory drug
  • Prevention

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this